HLA-C and melanoma: In order to establish a strategy that allows to distinguish TCR-independent HLA-C staining from epitope-specific HLA-C*07:02 multimer staining, we generated a second HLA-C*07:02-restricted multimer, refolded with a melanoma antigen (nonameric MAGE-A12-derived peptide VRIGHLYIL; amino acids 170–178) and developed a HLA-C multimer double staining protocol.